Abstract
Fedratinib (INREBIC (R)) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. In August 2019, fedratinib rece......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
